Antirheumatic Agent Drug Class List

Drugs in Drug Class: Antirheumatic Agent

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-001	Sep 10, 1998	AB	RX	Yes	No
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-002	Sep 10, 1998	AB	RX	Yes	Yes
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998		RX	Yes	Yes
Valeant Pharms Intl	CUPRIMINE	penicillamine	CAPSULE;ORAL	019853-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Valeant Pharms Intl	CUPRIMINE	penicillamine	CAPSULE;ORAL	019853-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Mylan Speciality Lp	DEPEN	penicillamine	TABLET;ORAL	019854-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes
Teva Pharms	HYDROXYCHLOROQUINE SULFATE	hydroxychloroquine sulfate	TABLET;ORAL	040081-001	Sep 30, 1994	AB	RX	No	No

Market dynamics and patent landscape for antirheumatic agents: exclusivity timelines, Orange Book/biosimilar risks, and generic and biosimilar entry scenarios

Last updated: June 17, 2026

The antirheumatic market is dominated by biologics and targeted small molecules, with IP end-dates and exclusivity windows driven by patent estates plus biologics licensure and interchangeability rules. The practical entry risk for competitors is concentrated in (1) remaining composition-of-matter and formulation/device IP for originators, (2) method-of-use claims tied to approved dosing and patient subsets, and (3) pathway leverage via biosimilar approval (for biologics) or Paragraph IV ANDA challenges (for small molecules). Commercial exposure clusters in TNF inhibitors, IL-6/IL-6R blockers, IL-1 targeting therapies, costimulatory modulators, JAK inhibitors, and oral PDE4 inhibitor programs, with the steepest near-term erosion typically occurring when multi-asset biologic patent families roll off and when small-molecule reference products approach 7-year/12-year biologics and 5-year/6-month exclusivity boundaries.

Which antirheumatic drugs drive the current patent and revenue footprint?

Antirheumatic agents split into two patent-risk regimes: biologics (fractionated patent estates plus BLA data exclusivity mechanics) and small molecules (ANDA-driven generic competition with Paragraph IV leverage).

How do biologics change the patent landscape in antirheumatics?

• Biologics competition is primarily via biosimilars under the Biologics Price Competition and Innovation Act (BPCIA), where technical and legal leverage often focuses on manufacturing comparability, interchangeability status, and lingering patent thickets.
• Patent estates for biologics include composition-of-matter, method-of-use, formulation, and delivery-device claims that can delay biosimilar commercialization even after regulatory approval.

How do small-molecule antirheumatics differ?

• Small molecules rely on ANDAs and Paragraph IV challenges tied to Orange Book-listed patents.
• Formulation, dosing regimen, and polymorph/process patents often control “at-risk” launch dates more than pharmacological mechanism patents.

What therapeutic targets dominate patent breadth across the class?

Across antirheumatic agents, the highest claim density typically maps to:

• TNF-alpha pathway (multiple monoclonals)
• IL-6/IL-6R pathway
• IL-17 axis in psoriatic and related inflammatory arthritis indications
• JAK signaling nodes (oral small molecules)
• Co-stimulation (T-cell pathway modulators)
• IL-1 blockade and IL-1 receptor biology
• PDE4 and broader inflammatory signaling in select indications

What patents protect key antirheumatic agents and how many patents exist per family?

Featured-snippet answer: Patent estates for leading antirheumatic agents typically include multiple families covering composition-of-matter plus secondary protection around formulation, dosing, and manufacturing processes. Without drug-specific identification, the class-level estimate is that top commercial programs usually carry 10 to 30 active patent assets globally per major product line, with the highest concentration in the US due to Orange Book listing practices and US litigation posture.

What patent categories most often delay generics or biosimilars?

1. Composition-of-matter and biologic sequence/construct claims
2. Method-of-use tied to labeled dosing regimens and clinical endpoints
3. Formulation or delivery-device claims (injector systems, stability, excipients)
4. Manufacturing process and purification claims
5. Switching and patient-selection claims that map to label wording

Which claim types are most litigation-prone?

• Orange Book patents that are easy to compare against ANDA product characteristics are the most frequently litigated in Paragraph IV actions.
• For biologics, manufacturing/process and formulation/device claims are common pressure points because even a biosimilar that matches structure-function can still run into non-infringing or “carve-out” arguments.

When do antirheumatic exclusivities and patent terms expire in the US?

Featured-snippet answer: Exclusivity in antirheumatics is driven by FDA exclusivity periods (where applicable) plus patent expiry dates. For small molecules, Orange Book-listed patents frequently govern launch timing for ANDAs. For biologics, even after biosimilar approval, patent litigation can still defer commercial sale.

How does FDA exclusivity interact with patent expiry for small molecules?

• New molecular entities: regulatory exclusivity typically creates a baseline time gate.
• After exclusivity, competitors can file ANDAs and potentially pursue Paragraph IV depending on patent listing status.
• Launch timing can still be delayed by injunction risk or settlement.

How does BPCIA affect effective exclusivity for biologics?

• Biosimilars can gain regulatory permission through the abbreviated pathway, but patent disputes under BPCIA can delay market entry.
• “Marketing date” effects can be linked to settlement agreements and shared dispute resolution timelines.

What patent expiration dates matter most for generic entry risks in antirheumatic small molecules?

Featured-snippet answer: For small-molecule antirheumatics, generic entry risk concentrates on the latest-to-expire Orange Book patent in the reference product’s listing set, especially if method-of-use or formulation patents remain.

What is the typical at-risk generic timeline?

• ANDA submission can occur before patent expiry if a Paragraph IV certification is made.
• Commercial entry can be blocked until patent expiry or until a settlement permits earlier launch.
• If litigation is active, courts can delay effective launch through injunction or resolution timing.

How do formulation and polymorph/process patents affect at-risk launches?

• Even if the active ingredient is off-patent, a generic can be held back if it must match formulation attributes covered by formulation patents.
• Polymorph, salt selection, particle size, or process claims can become the key determinants of “design-around” feasibility.

When do biosimilars of antirheumatic biologics face litigation and settlement effects?

Featured-snippet answer: For antirheumatic biologics, biosimilar launch timing often hinges less on FDA approval timing and more on patent dispute resolution and settlement terms.

What does BPCIA litigation typically target?

• Determination of the relevant patent list and infringement arguments
• Product similarity and whether differences avoid infringement of method-of-use, formulation, or manufacturing claims
• “Safe harbor” and notice/dispute timing mechanics that affect procedural outcomes

What settlement terms are commonly seen in antirheumatics?

• License agreements permitting commercial sale on a date certain
• At-risk carve-outs: delayed launches contingent on later generic/biosimilar milestones
• Royalty structures or market allocation clauses

What is the Orange Book status of antirheumatic reference products and how does it guide launch calendars?

Featured-snippet answer: Orange Book listings define the actionable patent surface for ANDAs. Launch calendars depend on identifying the latest expiring listed US patents, then mapping to Paragraph IV posture.

How to interpret Orange Book coverage for antirheumatic products

• Multiple patents can cover a single active ingredient across different product strengths and dosage forms.
• Not all patents block generic approval, but all listed patents can become litigation candidates once an ANDA is filed.

What patterns show up across antirheumatic Orange Book portfolios?

• Device and formulation patents are frequently relevant for subcutaneous delivery products.
• Method-of-use patents are common where labeling includes specific dosing regimens and patient populations.

How strong is the patent estate for antirheumatic drugs by mechanism class?

Featured-snippet answer: Patent strength is usually highest where originators maintain dense portfolios around (1) biologic construct and manufacturing, and (2) dosing/formulation and method-of-use claims in label language that competitors must mirror to achieve interchangeability or clinical comparability.

TNF inhibitors

• Typically have multiple biologic and device-related claim families.
• Biosimilar competition exists for many TNF agents, but litigation can still delay switch dynamics and commercial penetration.

IL-6 and IL-6R blockers

• Patent estates often include method-of-use and formulation protection linked to chronic inflammatory arthritis and systemic inflammatory indications.

IL-1 therapies

• Smaller patient populations still generate dense IP because clinical value is tied to specific indication subgroups and dosing protocols.

JAK inhibitors

• Small-molecule estates often show strong process and formulation protection plus secondary patent families to extend practical exclusivity.
• At-risk entry depends on whether the final listed Orange Book patents are expiring or still actively litigated.

Which companies are challenging antirheumatic patents and how does that affect market entry?

Featured-snippet answer: Patent challenges are driven by generics and biosimilars firms with established litigation infrastructure and commercialization capacity. Challenge activity tends to concentrate where originator patents are heavily listed and where originators have historically settled to avoid long injunction risk.

What counts as “challenge” in the antirheumatic class?

• Paragraph IV ANDA certifications for small molecules
• BPCIA patent litigation for biologics, including disputes over relevant patent lists and infringement

How challenge frequency correlates with patent density

• Higher patent counts increase the number of possible Paragraph IV targets.
• Denser estates typically produce more complex settlement outcomes, extending effective exclusivity.

What biosimilar entry risks exist for antirheumatic originators with late-expiring patents?

Featured-snippet answer: Even after regulatory approval, late-expiring patents tied to manufacturing, formulation, or method-of-use can delay biosimilar sales through injunction risk or settlement timing.

Risk map for late-expiring biologic portfolios

• Late-expiring formulation/device claims can block commercialization even when the biosimilar is approved.
• Manufacturing-process claims can complicate “design around” options because comparability is required for approval.

How does AbbVie’s immunology portfolio compare with other antirheumatic patent estates?

Featured-snippet answer: Originator portfolios in immunology typically combine biologic construct claims plus method-of-use and formulation/device coverage. In US practice, the comparative strength shows up in how many Orange Book-listed or US-listed patents remain active near the anticipated biosimilar or generic entry window.

What comparison is actionable for business?

• Compare the latest expiring patents in the US and whether they are already litigated.
• Compare settlement history: how often disputes end in early entry permission versus injunction-driven delays.
• Compare remaining formulation/device and method-of-use claims, which often determine commercial entry rather than FDA approval date.

Which antirheumatic delivery systems have the most formulation/device patent exposure?

Featured-snippet answer: Subcutaneous injection systems and chronic administration formulations tend to attract device and formulation patents that influence generic/biosimilar design-around and commercialization timing.

Common device and formulation claim hooks

• Injector mechanics
• Stability, viscosity, and excipient selection
• Administration workflows and user handling constraints
• Shelf-life and storage conditions that tie to label instructions

What generic launch scenarios exist for antirheumatic drugs as patents roll off?

Featured-snippet answer: Three scenarios dominate: (1) at-expiry launch after patent expiry, (2) earlier launch permitted by settlement, and (3) delayed launch due to unresolved litigation.

Scenario 1: clean expiry

• Generic launches immediately after the last listed patent expiry and exclusivity periods end.

Scenario 2: settlement-permitted early launch

• Launch date is moved forward via settlement and license structure.

Scenario 3: litigation delay

• Courts maintain an injunction or disputes remain unresolved beyond the scheduled market date.

What manufacturing and IP barriers block antirheumatic competitors even with regulatory approval?

Featured-snippet answer: For antirheumatics, the practical barrier is often patent infringement analysis against formulation/device/method-of-use claims, plus the need to match clinical comparability and label dosing.

Manufacturing barrier patterns

• Matching particle size, aggregation behavior, or lyophilized product characteristics where formulation patents apply.
• Maintaining consistency across lots to satisfy comparability and avoid prosecution leverage tied to “material differences” in process.

How much revenue exposure do antirheumatic patent cliffs create for originators?

Featured-snippet answer: Revenue exposure typically tracks the proportion of total sales tied to the US and to indications with high persistence. Patent cliffs create the steepest near-term exposure when the last active US patent expires while biosimilar or generic alternatives are already regulatory-approved or are procedurally “ready to launch.”

Where exposure tends to concentrate

• Chronic autoimmune indications with high continuity of therapy
• Products with limited payer restrictions and strong market penetration
• Portfolio items that retain label exclusivity while facing ramping competitors

Key Takeaways

• Antirheumatic patent dynamics are dominated by dense IP estates around biologic constructs and manufacturing plus US Orange Book-listed patents for small molecules.
• Generic and biosimilar launch timing is often governed by the latest expiring US listed patents and by settlement or injunction outcomes, not FDA approval dates alone.
• Formulation and method-of-use patents are repeat drivers of delayed market entry, particularly for delivery-device and chronic dosing regimens.
• Competitive entry risk concentrates where late-expiring claims remain unexpired or are actively litigated near the predicted launch calendar.
• For business planning, the actionable focus is the US “latest-to-expire” listed patent set, litigation posture, and settlement history, mapped to each dosage form and patient indication.

FAQs

1. How do Orange Book listings determine when antirheumatic generics can launch in the US?
2. What makes biosimilar entry in antirheumatic biologics hinge on patents after FDA approval?
3. Which antirheumatic patent families most often survive generic/biosimilar design-around strategies?
4. How do settlement agreements in antirheumatic patent litigation typically change launch dates?
5. What factors most influence whether an antirheumatic biosimilar achieves interchangeability and faster uptake?

References (APA)

1. United States Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. United States Food and Drug Administration. (n.d.). Drugs@FDA. FDA.
3. United States Congress. (2010). Biologics Price Competition and Innovation Act (BPCIA), as part of the Affordable Care Act.